Journal of International Oncology››2019,Vol. 46››Issue (7): 410-414.doi:10.3760/cma.j.issn.1673-422X.2019.07.004
Previous ArticlesNext Articles
Zheng Shanshan, Guo Zhi, Chen Lina, Liu Xuanyong, Chen Liping, Huang Jiayi, Chen Xiao
Online:
2019-07-08Published:
2019-07-16Contact:
Guo Zhi E-mail:guozhi77@126.comSupported by:
Shenzhen Municipal Health System Scientific Research Project (SZLY2018003); 2018 Annual Medicine & Health Sanming Project of Cancer Hospital & Shenzhen Hospital Chinese Academy of Medical Sciences (2018-nk003)
Zheng Shanshan, Guo Zhi, Chen Lina, Liu Xuanyong, Chen Liping, Huang Jiayi, Chen Xiao. Empirical versus diagnosticdriven antifungal therapy for hematological malignancies patients with invasive fungal disease[J]. Journal of International Oncology, 2019, 46(7): 410-414.
[1] 张雪云, 刘晓东, 史志勇, 等. 急性白血病造血干细胞移植后合并肺部真菌感染的临床分析[J]. 肿瘤预防与治疗, 2018, 31(3): 178182. DOI: 10.3969/j.issn.16740904.2018.03.004. [2] 中国侵袭性真菌感染工作组. 血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则(第五次修订版)[J]. 中华内科杂志, 2017, 56(6): 453459. DOI: 10.3760/cma.j.issn.05781426.2017.06.015. [3] Young AY, Leiva Juarez MM, Evans SE. Fungal pneumonia in patients with hematologic malignancy and hematopoietic stem cell transplantation[J]. Clin Chest Med, 2017, 38(3): 479491. DOI: 10.1016/j.ccm.2017.04.009. [4] Herbrecht R, Caillot D, Cordonnier C, et al. Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation[J]. J Antimicrob Chemother, 2012, 67(11): 27312738. DOI: 10.1093/jac/dks266. [5] Cesaro S, Tridello G, Castagnola E, et al. Retrospective study on the incidence and outcome of proven and probable invasive fungal infections in highrisk pediatric oncohematological patients[J]. Eur J Haematol, 2017, 99(3): 240248. DOI: 10.1111/ejh.12910. [6] Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomographybased preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study[J]. Clin Infect Dis, 2005, 41(9): 12421250. DOI: 10.1086/496927. [7] Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for highrisk, febrile, neutropenic patients: a randomized, controlled trial[J]. Clin Infect Dis, 2009, 48(8): 10421051. DOI: 10.1086/597395. [8] Barnes R, Earnshaw S, Herbrecht R, et al. Economic comparison of an empirical versus diagnosticdriven strategy for treating invasive fungal disease in immunocompromised patients[J]. Clin Ther, 2015, 37(6): 13171328.e2. DOI: 10.1016/j.clinthera.2015.03.021. [9] Pagano L, Caira M, Nosari A, et al. The use and efficacy of empirical versus preemptive therapy in the management of fungal infections: the HEMA eChart Project[J]. Haematologica, 2011, 96(9): 13661370. DOI: 10.3324/haematol.2011.042598. [10] 胡炯. 未确定侵袭性真菌病的诊断和治疗:血液病/恶性肿瘤患者侵袭性真菌病的诊断标准和治疗原则解读[J]. 中华内科杂志, 2017, 56(6): 395397. DOI: 10.3760/cma.j.issn.05781426.2017.06.002. [11] Gamaletsou MN, Walsh TJ, Sipsas NV. Invasive fungal infections in patients with hematological malignancies: emergence of resistant pathogens and new antifungal therapies[J]. Turk J Haematol, 2018, 35(1): 111. DOI: 10.4274/tjh.2018.0007. |
[1] | Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma: a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331. |
[2] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[3] | Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358. |
[4] | Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363. |
[5] | Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369. |
[6] | Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381. |
[7] | Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266. |
[8] | Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan.Progress of ferroptosis-related mechanisms in osteosarcoma[J]. Journal of International Oncology, 2024, 51(5): 308-311. |
[9] | Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong.Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(4): 210-216. |
[10] | Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234. |
[11] | Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238. |
[12] | Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150. |
[13] | Qian Xiaotao, Shi Ziyi, Hu Ge.A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(3): 151-156. |
[14] | Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing.Progress of radiotherapy in oligometastatic non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 170-174. |
[15] | Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||